Research & Literature

Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.

Wang J, Zhang B, Liu W, et al.

Familial cancer 2016; (15(1)):99-104 doi:10.1007/s10689-015-9828-6.

Biochemical Testing in Patients with Neuroendocrine Tumors.

Granberg D

Frontiers of hormone research 2015; (44()):24-39 doi:10.1159/000381981.

Spontaneous lesions in endocrine glands of experimental Wistar rats and beagle dogs.

Nataraju GJ, Ranvir RK, Kothule VR, et al.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 2016; (68(1)):1-13.

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.

Phan AT, Kunz PL, Reidy-Lagunes DL

Clinical advances in hematology & oncology : H&O 2015; (13(5 Suppl 5)):1-18; quiz 1 p following 18.

Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.

Frank-Raue K, Raue F

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2015; (204()):139-56 doi:10.1007/978-3-319-22542-5_6.

Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.

Narayanan S, Kunz PL

Hematology/oncology clinics of North America 2016; (30(1)):163-77.

Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.

Saif MW

Expert opinion on pharmacotherapy 2016; (17(3)):443-56 doi:10.1517/14656566.2016.1127914.

Thyroid Hormone Replacement in Patients Following Thyroidectomy for Thyroid Cancer.

Hannoush ZC, Weiss RE

Rambam Maimonides medical journal 2016; (7(1)) doi:10.5041/RMMJ.10229.

Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.

Gut P, Czarnywojtek A, Fischbach J, et al.

Archives of medical science : AMS 2016; (12(1)):1-9 doi:10.5114/aoms.2016.57577.

Clinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma.

Lee MH, Lee JH, Seol HJ, et al.

Brain tumor research and treatment 2016; (4(1)):1-7 doi:10.14791/btrt.2016.4.1.1.

ANESTHETIC MANAGEMENT IN UNEXPECTED EXTRA- ADRENAL PHEOCROMOCYTOMA PRESENTING WITH THORACIC SPINAL CORD COMPRESSION.

El Kouny A, Al Harbi M, Arif RM, et al.

Middle East journal of anaesthesiology 2016; (23(4)):485-9.

Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.

Coriat R, Walter T, Terris B, et al.

The oncologist 2016; (21(10)):1191-1199 doi:10.1634/theoncologist.2015-0476.

[Medullary thyroid carcinoma in a 10-month-old child with multiple endocrine neoplasia 2B].

Mathiesen JS, Døssing H, Bender L, Godballe C

Ugeskrift for laeger 2014; (176(5A)).

[Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].

Bencsiková B

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2016; (29(4)):253-8 doi:10.14735/amko2016253.

Relationship of each anterior pituitary hormone deficiency to the size of non-functioning pituitary adenoma in the hospitalized patients.

Mukai K, Kitamura T, Tamada D, et al.

Endocrine journal 2016; (63(11)):965-976 doi:10.1507/endocrj.EJ16-0168.

Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.

Ito T, Hijioka S, Masui T, et al.

Journal of gastroenterology 2017; (52(1)):9-18 doi:10.1007/s00535-016-1250-9.

Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.

Fazio N, Milione M

Cancer treatment reviews 2016; (50()):61-67 doi:10.1016/j.ctrv.2016.08.006.

Acromegaly: clinical features at diagnosis.

Vilar L, Vilar CF, Lyra R, et al.

Pituitary 2017; (20(1)):22-32 doi:10.1007/s11102-016-0772-8.

Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.

Ryan P, Phan AT, Adelman DT, Iwasaki M

Clinical journal of oncology nursing 2016; (20(6)):E139-E146 doi:10.1188/16.CJON.E139-E146.

[Implementation of multidisciplinary team in the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm].

Zhang P, Shen L

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2016; (19(11)):1205-1210.

Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database.

Giusti F, Cianferotti L, Boaretto F, et al.

Endocrine 2017; (58(2)):349-359 doi:10.1007/s12020-017-1234-4.

Diagnosis and Treatment of Pituitary Adenomas: A Review.

Molitch ME

JAMA 2017; (317(5)):516-524 doi:10.1001/jama.2016.19699.

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life.

Severi S, Grassi I, Nicolini S, et al.

OncoTargets and therapy 2017; (10()):551-557 doi:10.2147/OTT.S97584.

Urinary steroid metabolites in a case of florid Ectopic Cushing's syndrome and clinical correlations.

Kyriacou A, Stepien KM, Issa B

Hormones (Athens, Greece) 2016; (15(4)):540-547 doi:10.14310/horm.2002.1695.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(11)):1793-1796 doi:10.2967/jnumed.117.192450.

Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China.

Jin K, Luo G, Xu J, et al.

Oncology letters 2017; (13(5)):3163-3168 doi:10.3892/ol.2017.5834.

A rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's disease.

Streuli R, Krull I, Brändle M, et al.

Endocrinology, diabetes & metabolism case reports 2017; (2017()) doi:10.1530/EDM-17-0058.

Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.

Lawal IO, Ololade KO, Lengana T, et al.

Hellenic journal of nuclear medicine 2017; (20(2)):128-133 doi:10.1967/s002449910553.

The future: surgical advances in MEN1 therapeutic approaches and management strategies.

Sadowski SM, Cadiot G, Dansin E, et al.

Endocrine-related cancer 2017; (24(10)):T243-T260 doi:10.1530/ERC-17-0285.

[Multiple endocrine neoplasia].

Schaaf L, Raue F

Deutsche medizinische Wochenschrift (1946) 2017; (142(18)):1379-1389 doi:10.1055/s-0043-109522.

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide.

Kos-Kudła B, Ćwikła J, Ruchała M, et al.

Contemporary oncology (Poznan, Poland) 2017; (21(2)):115-122 doi:10.5114/wo.2017.68619.

The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.

Tirosh A, Kebebew E

Future oncology (London, England) 2018; (14(2)):111-122 doi:10.2217/fon-2017-0393.

The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

Fazio N, Ungaro A, Spada F, et al.

Journal of thoracic disease 2017; (9(Suppl 15)):S1501-S1510 doi:10.21037/jtd.2017.06.14.

The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.

Bodei L, Ćwikla JB, Kidd M, Modlin IM

Journal of thoracic disease 2017; (9(Suppl 15)):S1511-S1523 doi:10.21037/jtd.2017.09.82.

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, et al.

The oncologist 2018; (23(4)):422-432 doi:10.1634/theoncologist.2017-0364.

Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.

Alexandraki KI, Karapanagioti A, Karoumpalis I, et al.

BioMed research international 2017; (2017()):9856140 doi:10.1155/2017/9856140.

Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1.

Wong CL, Fok CK, Tam VH

Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-18-0006.

Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.

Guilmette JM, Nosé V

Advances in anatomic pathology 2019; (26(1)):13-30 doi:10.1097/PAP.0000000000000201.

Incidental Detection of Parathyroid Adenoma on Somatostatin Receptor PET/CT and Incremental Role of 18F-Fluorocholine PET/CT in MEN1 Syndrome.

Arora S, Damle NA, Passah A, et al.

Nuclear medicine and molecular imaging 2018; (52(3)):238-242 doi:10.1007/s13139-018-0520-2.

BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

Mirakhur B, Pavel ME, Pommier RF, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018; doi:10.4158/EP-2018-0296.

Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma.

Raue F, Frank-Raue K

Journal of the Endocrine Society 2018; (2(8)):933-943 doi:10.1210/js.2018-00178.

The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.

Sorbye H, Baudin E, Perren A

Endocrinology and metabolism clinics of North America 2018; (47(3)):683-698 doi:10.1016/j.ecl.2018.05.001.

Carcinoid syndrome: update on the pathophysiology and treatment.

Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP

Clinics (Sao Paulo, Brazil) 2018; (73(suppl 1)):e490s doi:10.6061/clinics/2018/e490s.

Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome.

Shogbesan O, Abdulkareem A, Pappachen B, Altomare J

Case reports in gastroenterology 2018; (12(2)):396-401 doi:10.1159/000490522.

Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.

Boucher JE, Sommers R

Clinical journal of oncology nursing 2018; (22(5)):565-568 doi:10.1188/18.CJON.565-568.

Multiple Endocrine Neoplasia Type 2B Presents Early in Childhood but Often Is Undiagnosed for Years.

Makri A, Akshintala S, Derse-Anthony C, et al.

The Journal of pediatrics 2018; (203()):447-449 doi:10.1016/j.jpeds.2018.08.022.

Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Pavel ME, Phan AT, Wolin EM, et al.

The oncologist 2019; (24(4)):463-474 doi:10.1634/theoncologist.2018-0217.

ENDOCRINE OUTCOMES OF TRANSSPHENOIDAL SURGERY FOR PITUITARY APOPLEXY VERSUS ELECTIVE SURGERY FOR PITUITARY ADENOMA.

Marcet P, Paluzzi J, Morrison A, Vale FL

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(4)):353-360 doi:10.4158/EP-2018-0488.

[Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].

Klöppel G

Der Pathologe 2019; (40(3)):211-219 doi:10.1007/s00292-019-0594-3.

Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database.

Bonvalot S, Gaignard E, Stoeckle E, et al.

Annals of surgical oncology 2019; (26(7)):2286-2293 doi:10.1245/s10434-019-07421-9.

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.

Stueven AK, Kayser A, Wetz C, et al.

International journal of molecular sciences 2019; (20(12)) doi:10.3390/ijms20123049.

First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome.

Chiloiro S, Capoluongo ED, Schinzari G, et al.

Frontiers in endocrinology 2019; (10()):365 doi:10.3389/fendo.2019.00365.

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

Hennrich U, Kopka K

Pharmaceuticals (Basel, Switzerland) 2019; (12(3)) doi:10.3390/ph12030114.

Diagnostic fficiency of 68Ga-DOTATATE PET/CT as ompared to 99mTc-Octreotide SPECT/CT andonventional orphologic odalities in euroendocrine umors.

Fallahi B, Manafi-Farid R, Eftekhari M, et al.

Asia Oceania journal of nuclear medicine & biology 2019; (7(2)):129-140 doi:10.22038/AOJNMB.2019.39392.1263.

Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support in a Patient with Panhypopituitarism: A Case Report.

Huang D, Kreitler K, Tilton S, et al.

Cureus 2019; (11(6)):e4995 doi:10.7759/cureus.4995.

[Gastroenteropancreatic neuroendocrine tumors].

Breitling LP, Rinke A, Gress TM

Deutsche medizinische Wochenschrift (1946) 2019; (144(21)):1509-1521 doi:10.1055/a-0865-0061.

177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.

Das S, Al-Toubah T, El-Haddad G, Strosberg J

Expert review of gastroenterology & hepatology 2019; (13(11)):1023-1031 doi:10.1080/17474124.2019.1685381.

The Pancreatic Endocrine Tumors - Experience of First Surgical Clinic Iasi.

Târcoveanu E, Lupascu C, Vasilescu A, et al.

Chirurgia (Bucharest, Romania : 1990) 2019; (114(5)):639-649.

[Multiple endocrine neoplasia type 1: about a case].

Anguezomo G, El Mghari G, El Ansari N

The Pan African medical journal 2019; (33()):238 doi:10.11604/pamj.2019.33.238.18053.

The Role of Lithium in Management of Endocrine Tumors-A Comprehensive Review.

Thakur S, Tobey A, Klubo-Gwiezdzinska J

Frontiers in oncology 2019; (9()):1092 doi:10.3389/fonc.2019.01092.

Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.

Crown A, Rocha FG, Raghu P, et al.

Journal of surgical oncology 2020; (121(3)):480-485 doi:10.1002/jso.25812.

Thyroid carcinoma with atypical metastasis to the pituitary gland and unexpected postmortal diagnosis.

Popławska-Kita A, Wielogórska M, Poplawski Ł, et al.

Endocrinology, diabetes & metabolism case reports 2020; (2020()).

Carcinoid Syndrome: A Review.

Gade AK, Olariu E, Douthit NT

Cureus 2020; (12(3)):e7186 doi:10.7759/cureus.7186.

Neuroendocrine neoplasm update: toward universal nomenclature.

Rindi G, Inzani F

Endocrine-related cancer 2020; (27(6)):R211-R218.

Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome.

Freytag M, Herrlinger U, Hauser S, et al.

BMC cancer 2020; (20(1)):355 doi:10.1186/s12885-020-06809-1.

Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms.

Palmieri LJ, Dermine S, Barré A, et al.

Journal of clinical medicine 2020; (9(6)) doi:10.3390/jcm9061860.

Solitary circumscribed neuroma of the conjunctiva: Differential diagnosis from neurofibroma is a must?

Kiyat P, Selver OB, Akalin T, Palamar M

Arquivos brasileiros de oftalmologia 2020; (83(5)):427-429 doi:10.5935/0004-2749.20200084.

Gastrointestinal neuroendocrine tumors in 2020.

Ahmed M

World journal of gastrointestinal oncology 2020; (12(8)):791-807 doi:10.4251/wjgo.v12.i8.791.

Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report.

Di Buono G, Bonventre G, Badalamenti G, et al.

International journal of surgery case reports 2020; (77S()):S105-S108 doi:10.1016/j.ijscr.2020.09.120.

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.

Li SY, Ding YQ, Si YL, et al.

Frontiers in endocrinology 2020; (11()):543246 doi:10.3389/fendo.2020.543246.

Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.

Shi H, Chen L, Zhang Q, et al.

Pancreas 2020; (49(10)):1378-1382 doi:10.1097/MPA.0000000000001693.

Complete remission of Cdx-2 positive primary testicular carcinoid tumor: 10-years follow-up and literature review.

Widmeier E, Füllgraf H, Waller CF

BMC urology 2020; (20(1)):197 doi:10.1186/s12894-020-00768-2.

Recurrence of a neuroendocrine tumor of adrenal origin: a case report with more than a decade follow-up.

Rahmani F, Tohidi M, Dehghani M, et al.

BMC endocrine disorders 2021; (21(1)):9 doi:10.1186/s12902-020-00673-7.

Multiple Endocrine Neoplasia Type 1 Syndrome: A Case Report and Review of Literature.

Boro H, Kubihal S, Arora S, et al.

Cureus 2020; (12(12)):e12073 doi:10.7759/cureus.12073.

Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.

Baeg K, Harris C, Naparst MS, et al.

BMC cancer 2021; (21(1)):146 doi:10.1186/s12885-021-07868-8.

Metabolic changes in serum steroids for diagnosing and subtyping Cushing's syndrome.

Ahn CH, Lee C, Shim J, et al.

The Journal of steroid biochemistry and molecular biology 2021; (210()):105856 doi:10.1016/j.jsbmb.2021.105856.

Diagnostic Utility of INSM1 in Medullary Thyroid Carcinoma.

Seok JY, Kang M, De Peralta-Venturina M, Fan X

International journal of surgical pathology 2021; (29(6)):615-626 doi:10.1177/1066896921995935.

A comparative study of functioning and non-functioning pituitary adenomas.

Qin J, Li K, Wang X, Bao Y

Medicine 2021; (100(14)):e25306 doi:10.1097/MD.0000000000025306.

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.

Patel M, Tena I, Jha A, et al.

Frontiers in endocrinology 2021; (12()):625312 doi:10.3389/fendo.2021.625312.

Three pediatric patients with primary hyperparathyroidism caused by parathyroid adenoma.

Oh A, Lee Y, Yoo HW, Choi JH

Annals of pediatric endocrinology & metabolism 2022; (27(2)):142-147 doi:10.6065/apem.2142006.003.

Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.

Chevalier B, Dupuis H, Jannin A, et al.

Frontiers in endocrinology 2021; (12()):678869 doi:10.3389/fendo.2021.678869.

Theragnostics in Neuroendocrine Tumors.

Rodrigues M, Svirydenka H, Virgolini I

PET clinics 2021; (16(3)):365-373 doi:10.1016/j.cpet.2021.03.001.

Giant parathyroid adenoma diagnosed by brown tumour, a clinical manifestation of primary hyperparathyroidism: A case report.

Yigit B, Tanal M, Citgez B

JPMA. The Journal of the Pakistan Medical Association 2021; (71(4)):1266-1269 doi:10.47391/JPMA.393.

A germline c.1546dupC MEN1 mutation in an MEN1 family: A case report.

Cho YY, Chung YJ

Medicine 2021; (100(25)):e26382 doi:10.1097/MD.0000000000026382.

Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.

Dawod M, Gordoa TA, Cives M, et al.

Current treatment options in oncology 2021; (22(8)):73 doi:10.1007/s11864-021-00863-y.

Neuroendocrine Carcinomas of the Digestive Tract: What Is New?

Pellat A, Cottereau AS, Terris B, Coriat R

Cancers 2021; (13(15)) doi:10.3390/cancers13153766.

Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation.

Walczyk A, Zgubieński K, Chmielewski G, et al.

Diagnostics (Basel, Switzerland) 2021; (11(8)) doi:10.3390/diagnostics11081448.

Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.

Kole C, Charalampakis N, Vailas M, et al.

Cancer immunology, immunotherapy : CII 2022; (71(4)):761-768 doi:10.1007/s00262-021-03046-8.

Use of Selective Arterial Calcium Stimulation Testing in Identification of Insulinoma in a Patient After Bariatric Surgery.

Szczepanski JM, Hissong E, Manthei DM

Laboratory medicine 2022; (53(2)):e40-e43 doi:10.1093/labmed/lmab071.

Neuroendocrine Neoplasm of the Breast Presenting as a Liver Metastasis: A Rare Diagnostic Challenge.

Masab M, Gross A, Flanagan M, et al.

Cureus 2021; (13(8)):e16860 doi:10.7759/cureus.16860.

Pheochromocytoma presenting as a pancreatic mass: Avoiding a dangerous pitfall in endoscopic ultrasound-guided fine needle aspiration biopsy using GATA3 immunostain.

Kebe Radulović M, Strojan Fležar M

Cytopathology : official journal of the British Society for Clinical Cytology 2022; (33(1)):127-131 doi:10.1111/cyt.13060.

Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.

Shi M, Fan Z, Xu J, et al.

Biochimica et biophysica acta. Reviews on cancer 2021; (1876(2)):188637 doi:10.1016/j.bbcan.2021.188637.

Hereditary paraganglioma presenting with atypical symptoms: Case report.

Eguchi S, Ono R, Sato T, et al.

Medicine 2021; (100(46)):e27888 doi:10.1097/MD.0000000000027888.

Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

Carter AM, Kumar N, Herring B, et al.

Oncogenesis 2021; (10(12)):83 doi:10.1038/s41389-021-00372-5.

Agenesis of the dorsal pancreas with chronic suppurative pancreatitis: Case report and literature review.

Xia LZ, Bu XF, Jiang PC, et al.

Medicine 2021; (100(49)):e28137 doi:10.1097/MD.0000000000028137.

Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract.

Georgescu TA, Bohiltea RE, Munteanu O, et al.

Medicina (Kaunas, Lithuania) 2021; (57(12)) doi:10.3390/medicina57121338.

Transduodenal resection of periampullary neuroendocrine tumor: A case report.

AlQatari AA, Fallatah RZ, AlQattan AS, et al.

Annals of medicine and surgery (2012) 2022; (73()):103126 doi:10.1016/j.amsu.2021.103126.

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.

Mete O, Wenig BM

Head and neck pathology 2022; (16(1)):123-142 doi:10.1007/s12105-022-01435-8.

Clinical Biology of the Pituitary Adenoma.

Melmed S, Kaiser UB, Lopes MB, et al.

Endocrine reviews 2022; (43(6)):1003-1037 doi:10.1210/endrev/bnac010.

Cushing syndrome secondary to a mediastinal carcinoid tumor: a case report.

Ershadi R, Vahedi M, Jahanbin B, et al.

International cancer conference journal 2022; (11(2)):152-157 doi:10.1007/s13691-022-00542-1.

Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

Canakis A, Lee LS

World journal of gastrointestinal endoscopy 2022; (14(5)):267-290 doi:10.4253/wjge.v14.i5.267.

Hedinger Syndrome: A Rare Cardiac Manifestation of Carcinoid Syndrome.

Ghukasyan H

Cureus 2022; (14(7)):e26528 doi:10.7759/cureus.26528.

A Comprehensive Review of Four Clinical Practice Guidelines of Acromegaly.

Ogedegbe OJ, Cheema AY, Khan MA, et al.

Cureus 2022; (14(9)):e28722 doi:10.7759/cureus.28722.

A Factorial Analysis on Visual Outcomes of Transsphenoidal Surgery for Pituitary Macroadenoma.

Ng BCF, Mak CH, Steffi CSY, et al.

Asian journal of neurosurgery 2022; (17(2)):280-285 doi:10.1055/s-0042-1751011.

Molecular and Anatomic Imaging of Neuroendocrine Tumors.

Szidonya L, Park EA, Kwak JJ, Mallak N

Surgical oncology clinics of North America 2022; (31(4)):649-671 doi:10.1016/j.soc.2022.06.009.

Preliminary experience with a new institutional tumor board dedicated to patients with neuroendocrine neoplasms.

Trikalinos NA, Hammill C, Liu J, et al.

Abdominal radiology (New York) 2022; (47(12)):4096-4102 doi:10.1007/s00261-022-03707-x.

Pancreatic Neuroendocrine Tumor (PNET) Presenting as a Pseudocyst: A Case Report.

Sedhai S, Mohammed F, Sahtiya S, et al.

Cureus 2022; (14(9)):e29617 doi:10.7759/cureus.29617.

Liver metastasis from rectal neuroendocrine neoplasm detected 15 years after primary resection.

Akabane M, Okubo S, Kinowaki K, et al.

Surgical case reports 2022; (8(1)):212 doi:10.1186/s40792-022-01569-5.

A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients.

Becx MN, Minczeles NS, Brabander T, et al.

Cancers 2022; (14(23)) doi:10.3390/cancers14235792.

Carcinoid tumors outside the abdomen.

Koehler K, Iams WT

Cancer medicine 2023; (12(7)):7893-7903 doi:10.1002/cam4.5564.

Collision of Two Tumors: A Case Report of a Lung Adenocarcinoma With Metastasis to a Pituitary Adenoma.

Borhan MK, Tan FHS, Basry NSA

Journal of the ASEAN Federation of Endocrine Societies 2022; (37(2)):89-94 doi:10.15605/jafes.037.02.09.

Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines.

Mohamed A, Wu S, Hamid M, et al.

Cancers 2022; (15(1)) doi:10.3390/cancers15010295.

Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma.

Tsukamoto T, Miki Y

Japanese journal of radiology 2023; (41(8)):789-806 doi:10.1007/s11604-023-01400-7.

Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.

Park HK, Kwon GY

Journal of Korean medical science 2023; (38(11)):e85 doi:10.3346/jkms.2023.38.e85.

Cancer Care by Committee to be Superseded by Personal Physician-Patient Partnership Informed by Artificial Intelligence.

Turner JH

Cancer biotherapy & radiopharmaceuticals 2023; (38(8)):497-505 doi:10.1089/cbr.2023.0058.

MEN1 in a Patient With Nonsyndromic Familial Nonmedullary Thyroid Carcinoma.

Fitzgerald LA, Williamson S, Shakil J, Robbins RJ

JCEM case reports 2023; (1(1)):luac019 doi:10.1210/jcemcr/luac019.

Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors.

Möller K, Uhlig R, Gorbokon N, et al.

Molecular and cellular endocrinology 2024; (581()):112106 doi:10.1016/j.mce.2023.112106.

Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma.

Miao Y, Fan K, Peng X, et al.

Frontiers in endocrinology 2023; (14()):1241145 doi:10.3389/fendo.2023.1241145.

[Modern aspects influencing the management of patients with papillary thyroid cancer].

Skibitskaya MV, Kuznetsov NS

Khirurgiia 2023; 89-94 doi:10.17116/hirurgia202312189.

[Exocrine meets neuroendocrine: mimickers of pancreatic neuroendocrine neoplasms].

Karamitopoulou-Diamantis E

Pathologie (Heidelberg, Germany) 2024; (45(1)):42-49 doi:10.1007/s00292-023-01286-2.

Recurrent Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1 Syndrome.

Libánský P, Čarková J, Kushnir I, et al.

Physiological research 2023; (72(S4)):S423-S427 doi:10.33549/physiolres.935223.

The role of multidisciplinary team meeting histopathology review and its impact on revised reports: Analysis of a national quality improvement program.

O'Connor E, Treacy A, Mitchell A, Swan N

American journal of clinical pathology 2024; (161(6)):579-585 doi:10.1093/ajcp/aqad183.

Plasma tryptophan pathway metabolites quantified by liquid chromatography-tandem mass spectrometry as biomarkers in neuroendocrine tumor patients.

Johansen SU, Hansen T, Nordborg A, et al.

Journal of neuroendocrinology 2024; (36(3)):e13372 doi:10.1111/jne.13372.

PDP type brain tumor in association with multiple endocrine neoplasia type 1.

Einarsson HB, Frederiksen AL, Pedersen IS, et al.

Heliyon 2024; (10(6)):e27418 doi:10.1016/j.heliyon.2024.e27418.

Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.

Giri S, Sahoo J

World journal of gastroenterology 2024; (30(12)):1670-1675 doi:10.3748/wjg.v30.i12.1670.

[Current WHO classification (2022) of neuroendocrine neoplasms].

Buchstab O, Knösel T

Radiologie (Heidelberg, Germany) 2024; (64(7)):531-535 doi:10.1007/s00117-024-01295-z.

Acromegaly in humans and cats: Pathophysiological, clinical and management resemblances and differences.

Lopes-Pinto M, Marques PL, Lacerda-Nobre E, et al.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2024; (76()):101595 doi:10.1016/j.ghir.2024.101595.

Update in the management of gastroenteropancreatic neuroendocrine tumors.

Sedlack AJH, Varghese DG, Naimian A, et al.

Cancer 2024; (130(18)):3090-3105 doi:10.1002/cncr.35463.

Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B.

Greenberg LA

Primary care 2024; (51(3)):483-494 doi:10.1016/j.pop.2024.03.006.

Neuroendocrine Neoplasms.

Kamboj S, Guerra-Bauman F, Mahmud H, Waheed A

Primary care 2024; (51(3)):549-560 doi:10.1016/j.pop.2024.04.010.

Management of advanced high grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature.

Mohamed A, Trybula M, Asa SL, et al.

Endocrine-related cancer 2024; (31(10)).

PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC).

Sorbye H, Kong G, Grozinsky-Glasberg S, Strosberg J

Journal of neuroendocrinology 2025; (37(3)):e13443 doi:10.1111/jne.13443.

Dose-dependent relationship between levothyroxine and health-related quality of life in survivors of differentiated thyroid cancer.

Braafladt S, Allison H, Chung J, et al.

Surgery 2025; (179()):108799 doi:10.1016/j.surg.2024.07.057.

The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives.

Lauricella E, Vilisova S, Chaoul N, et al.

Expert review of neurotherapeutics 2025; (25(2)):245-258 doi:10.1080/14737175.2024.2417419.

An Update on the Management of Rectal Neuroendocrine Neoplasms.

Frydman A, Srirajaskanthan R

Current treatment options in oncology 2024; (25(11)):1461-1470 doi:10.1007/s11864-024-01267-4.

Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.

Sonnen AF, Verschuur AVD, Brosens LAA

Pathologie (Heidelberg, Germany) 2024; (45(Suppl 1)):74-82 doi:10.1007/s00292-024-01393-8.

Primary hyperparathyroidism due to a giant parathyroid adenoma presenting with pathological fractures and multiple brown tumors.

Meng J, Aboznadah WM, Pusztaszeri M, Larouche V

Endocrinology, diabetes & metabolism case reports 2024; (2024(4)).

A Reassessment of the Clinical Utility of 68Ga-DOTATATE PET/CT in Patients With Gastroenteropancreatic Neuroendocrine Tumors.

Prela O, Caveney B, Strawderman M, et al.

Journal of surgical oncology 2025; (131(7)):1336-1342 doi:10.1002/jso.28061.

Analysis of Urinary Metanephrines Using Liquid Chromatography Tandem Mass Spectrometry.

Thaitumu MN, Frank EL

Methods in molecular biology (Clifton, N.J.) 2025; (2891()):257-268 doi:10.1007/978-1-0716-4334-1_14.

Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.

Urman A, Schonman I, De Jesus-Acosta A

Current treatment options in oncology 2025; (26(2)):92-102 doi:10.1007/s11864-024-01283-4.

Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.

Frank-Raue K, Raue F

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2025; (223()):183-209 doi:10.1007/978-3-031-80396-3_7.

Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome.

Kerolles M, Mulders MCF, Mirzaian M, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(12)):e3980-e3988 doi:10.1210/clinem/dgaf263.

Size matters: Establishing a cut-off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines.

Kim S, Kim ER, Hong SN, et al.

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2025; (37(9)):962-971 doi:10.1111/den.15056.

Clinical/pathological features and survival outcomes of extra-pulmonary neuroendocrine carcinomas: A retrospective single-center series.

Benini L, Gervaso L, Frassoni S, et al.

Journal of neuroendocrinology 2025; (37(9)):e70057 doi:10.1111/jne.70057.

The Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management.

Gombert AJ, Nerantzinis AM, Li J, et al.

International journal of molecular sciences 2025; (26(13)) doi:10.3390/ijms26136080.

Contemporary review of middle ear adenomatous neuroendocrine tumors.

Shoman N

Current opinion in otolaryngology & head and neck surgery 2025; (33(5)):271-275 doi:10.1097/MOO.0000000000001075.

Tumor Differentiation and the Role of Nuclear Medicine Scintigraphy and Therapy.

Bolin JD

Journal of nuclear medicine technology 2025; (53(Suppl 1)):132S-140S doi:10.2967/jnmt.125.271082.

Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.

Kasajima A, Perren A, Klöppel G

Virchows Archiv : an international journal of pathology 2026; (488(1)):3-20 doi:10.1007/s00428-025-04296-y.

Expanding the therapeutic horizon of 177Lu-DOTATATE: a review of current evidence.

Minamimoto R, Kato K, Iwano S, et al.

Nagoya journal of medical science 2025; (87(4)):607-631 doi:10.18999/nagjms.87.4.607.

A Medically Managed Case of Acromegaly: A Case Report.

Bdour K, Al-Sarihin K, El Issa N, et al.

Cureus 2026; (18(1)):e101136 doi:10.7759/cureus.101136.

A rare case of ectopic cushing's syndrome caused by renal neuroendocrine tumor.

Sehatpour F, Panahi N, Ramezani-Binabaj M, et al.

Journal of diabetes and metabolic disorders 2026; (25(1)):79 doi:10.1007/s40200-026-01878-8.